Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Homozygous Familial Hypercholesterolaemia (HoFH)
View Full LandscapeTarget Indication
Homozygous Familial Hypercholesterolaemia (HoFH)
Clinical Trial
NCT04681170Last updated: 1/2/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Lojuxta
Lojuxta is indicated as an adjunct to a low?fat diet and other lipid?lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.
View on EMA